Investor FAQs

Show All
What does Stemline Therapeutics do?

Stemline Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. In December 2018, the FDA approved ELZONRIS, a targeted therapy directed to CD123, for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In November 2018, the European Medicines Agency (EMA) granted accelerated assessment to the marketing authorization application (MAA) of ELZONRIS in patients with BPDCN, which was submitted to the EMA in January 2019. ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and others. Other Stemline clinical candidates include SL-801, a novel oral small molecule reversible inhibitor of XPO1, which is currently in a Phase 1 trial of patients with advanced solid tumors and recent data was presented at the European Society of Medical Oncology (ESMO) annual conference; and SL-701, an immunotherapeutic which has completed a Phase 2 trial in patients with second-line glioblastoma and recent data were presented at the Society for Neuro-Oncology (SNO) annual conference.

What is Stemline’s Nasdaq ticker symbol?

Stemline Therapeutics can be found under the symbol STML.

When did Stemline become a publicly traded company?

Stemline’s initial public offering occurred on January 28, 2013.

Where is Stemline Therapeutics incorporated?

Stemline is incorporated in the state of Delaware.

Where is Stemline’s corporate headquarters located?

Stemline's corporate headquarters is located at the following address:

750 Lexington Avenue, 11th Floor
New York, NY 10022

Does Stemline pay a dividend?

Stemline does not pay a dividend at this time.

Who is Stemline's transfer agent?

Stemline’s transfer agent is:

Computershare Trust Company, N.A.
P.O. Box 43078
Providence, RI 02940
1-800-962-4284 (from the United States, Canada, Puerto Rico)
1-781-575-3120 (non-United States)

When does Stemline’s fiscal year end?

Stemline’s fiscal year ends on December 31.